← All indications
Hemorrhagic Fever, Ebola
A highly fatal, acute hemorrhagic fever caused by EBOLAVIRUS.
Drugs by status
Approved for this indication (7)
Phase 4 trials (2)
Phase 3 trials (6)
Phase 2 trials (15)
Phase 1 trials (25)
- avi-6002
- avi-7537
- ino-4201
- tkm-100201
- tkm-100802
- ebov gp vaccine
- ad5-ebov
- chad3-ebo-z
- hpiv3-ebovz gp vaccine
- marburg vaccine
- mva multi-filo ebola vaccine
- mva-ebo z
- vrc-eboadc069-00-vp
- vrc-eboadv018-00-vp
- vrc-ebodna012-00-vp
- vrc-ebodna023-00-vp
- vrc-mardna025-00-vp
- poly-iclc
- blood plasma
- galidesivir
- cad3-marburg vaccine
- matrix m1
- hpiv3/δhnf/ebovz gp vaccine
- chadox1 biebov
- gamezumab
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (21)
- Merck
- Bavarian Nordic
- Epicentre
- Emergency NGO Onlus
- National Institute of Allergy and Infectious Diseases (NIAID)
- Public Health England
- University of London
- Institut National de la Santé Et de la Recherche Médicale, France
- University of Sierra Leone
- University of Oxford
- Janssen Pharmaceutica NV
- Department of Health and Human Services
- Grameen Foundation
- World Vision of Ireland
- eHealth Africa
- Johnson and Johnson
- Government of Sierra Leone
- Government of the Democratic Republic of the Congo
- Centers for Disease Control and Prevention (CDC)
- Medecins Sans Frontieres
- Coalition for Epidemic Preparedness Innovations
Organization Involved with Phase 2 Indications (34)
- Beijing Institute of Pharmacology and Toxicology
- Clinical Research Management, Inc.
- Chimerix
- GlaxoSmithKline
- INC Research
- Centers for Disease Control and Prevention, China
- United States Army
- World Health Organization
- Duke University
- Policlinique Médicale Universitaire
- University of Lausanne
- Dalhousie University
- University of Basel
- Food and Drug Administration
- University of Kinshasa
- Redemption Hospital
- Ministry of Health & Sanitation
- Government of China
- University of North Carolina at Chapel Hill
- Medical Research Council-UVRI Uganda Research Unit on AIDS
- European Commission
- Bill and Melinda Gates Foundation
- Canadian Immunization Research Network
- The Liberia-US Clinical Trials Partnership Program, Partnership for Research on Ebola Virus in Liberia Project
- Sierra Leone-China Friendship Hospital
- Beijing Institute of Biotechnology
- Tianjin Cansino Biotechnology Inc
- EBOVAC2 Consortium
- University of Antwerp
- Government of Liberia
- +4 more
Organization Involved with Phase 1 Indications (32)
- BioCryst
- Sarepta Therapeutics
- Arbutus Biopharma Corporation
- Cerus Corporation
- Novavax
- Profectus BioSciences, Inc.
- The EMMES Corporation
- National Institutes of Health (NIH)
- Albert Schweitzer Hospital
- Johns Hopkins University
- Makerere University
- University of Hamburg
- University of Maryland
- Zhejiang University
- Department of Defense
- Quotient
- Accelovance
- NewLink Genetics Inc
- Centre Hospitalier Universitaire le Dantec
- New Orleans Center for Clinical Research
- PRACS
- Wellcome Trust
- University of Tuebingen
- ICON
- Canadian Institutes of Health Research (CIHR)
- German Center for Infection Research
- Leidos
- BioProtection Systems Corporation
- Clinical Trial Center North
- Philipps University of Marburg
- +2 more
Organization Involved with Other Experimental Indications (1)